Safety and efficacy of tazarotene foam for the treatment of acne vulgaris

Figures & data

Table 1 Reductions in lesion counts and improvement in Investigator’s Global Assessment at week 12¹

Primary efficacy variables	Study 1		Study 2
	Tazarotene foam N = 371	Vehicle foam N = 372	Tazarotene foam N = 373	Vehicle foam N = 369
Inflammatory lesions
Mean absolute reduction from Baseline	18.0	14.0	18.0	15.0
Mean percent reduction from Baseline	58%	45%	55%	45%
Non-inflammatory lesions
Mean absolute reduction from Baseline	28.0	17.0	26.0	18.0
Mean percent reduction from Baseline	55%	33%	57%	41%
Total lesions
Mean absolute reduction from Baseline	46.0	31.0	43.0	33.0
Mean percent reduction from Baseline	56%	39%	56%	43%
Investigator’s Global Assessment, n (%)
Minimum 2-grade improvement and IGA of 0 or 1	107 (29%)	60 (16%)	103 (28%)	49 (13%)

Abbreviation: IGA, Investigator’s Global Assessment.

Table 2 Incidence of adverse reactions at the application site in ≥1% of patients treated with tazarotene foam 0.1%¹

Adverse reactions at the application site	Tazarotene foam N = 744	Vehicle foam N = 741
Patients with any adverse reaction, n (%)	163 (22)	19 (3)
Irritation	107 (14)	9 (1)
Dryness	50 (7)	8 (1)
Erythema	48 (6)	3 (<1)
Exfoliation	44 (6)	3 (<1)
Pain	9 (1)	0
Photosensitivity (including sunburn)	8 (1)	3 (<1)
Pruritus	7 (1)	3 (<1)
Dermatitis	6 (1)	1 (<1)

Fabior® (Tazarotene) Foam 01% [package insert]Research Triangle Park, NCStiefel Laboratories, Inc2012

 Google Scholar